- VBI Vaccines will find out on November 30th whether its Hepatitis B vaccine - already approved in Israel - will be approved by the FDA in the US.
- Approval in the US - and Europe, where a marketing authorization is also being sought - could be a potential game-changer for the company, although this is a tricky market.
- VBI has several COVID vaccines in development, designed to complement existing, approved ones, which are early stage but focused on e.g. durability of response.
- VBI's use of Virus Like Particles and lipid layer of protection is novel and promising, and can also be applied to other infectious diseases and cancers.
- An approval next month could push the company's valuation past $1bn, in my view, representing 25% upside. And longer term, the outlook looks promising - although possibly only to die-hard biotech investors.
For further details see:
VBI Vaccines: Hepatitis Vaccine Approval Can Be A Catalyst For >$1bn Valuation